Skip to content
2000
Volume 19, Issue 5
  • ISSN: 1573-3998
  • E-ISSN: 1875-6417

Abstract

Aims: Diabetic patients are significantly stimulated by COVID-19 infection. The dreadful risk of COVID-19 mortality may be affected. In order to preserve precious lives, it is essential to comprehend how diabetes and COVID-19 are related, as well as how to manage diabetes. We aimed to focus on the mechanism, impact, and drug treatment of diabetes in COVID-19 patients. Methods: A comprehensive scrutiny of the published literature in diverse pharmaceutical and medical databases such as Google Scholar, PubMed, Science Direct, DOAJ etc., were successfully conducted and classified accordingly. Results: We discussed the severity of COVID-19 in diabetes patients. A patient with diabetes has a higher risk of COVID-19 mortality by influencing the development and prognosis of the disease. The recommended drugs for diabetes treatment in COVID-19 may reduce COVID-19 mortality. Conclusion: Metabolic syndrome diabetes is a risk factor enhancing the development and diagnosis of COVID-19. In order to treat diabetic patients who have COVID-19 infection, insulin is preferable over oral hypoglycemic medications.

Loading

Article metrics loading...

/content/journals/cdr/10.2174/1573399819666221006103113
2023-06-01
2025-05-25
Loading full text...

Full text loading...

/content/journals/cdr/10.2174/1573399819666221006103113
Loading

  • Article Type:
    Review Article
Keyword(s): ARBs; COVID-19; Diabetes; drug therapy; innate immunity; SARS-CoV-2
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test